Davern Capital Partners, LP

CIK: 0002003147Latest portfolio: $309.3M · Q4 2025

Holdings

14

Total Value

$309.3M

New Positions

14

Closed Positions

0

Top Holdings

#StockSharesValue% PortfolioType
1
PFEPFIZER INC
2,042,242$50.9M16.44%
2
REGNREGENERON PHARMACEUTICALS
52,420$40.5M13.08%
3
BNTXBIONTECH SE
371,216$35.3M11.43%
4
RPRXROYALTY PHARMA PLC
840,650$32.5M10.50%
5
ARGXARGENX SE
35,685$30.0M9.70%
6
LEGNLEGEND BIOTECH CORP
1,056,668$23.0M7.43%
7
ROIVROIVANT SCIENCES LTD
1,028,298$22.3M7.21%
8
ISIIONIS PHARMACEUTICALS INC
238,477$18.9M6.10%
9
NTRANATERA INC
78,650$18.0M5.83%
10
LLYELI LILLY & CO
8,307$8.9M2.89%
11
VRDNVIRIDIAN THERAPEUTICS INC
261,615$8.1M2.63%
12
MLYSMINERALYS THERAPEUTICS INC
210,648$7.6M2.47%
13
CGONCG ONCOLOGY INC
162,005$6.7M2.17%
14
ABVXABIVAX SA
48,502$6.5M2.11%

Sector Breakdown

Healthcare0.0% ($5.085140461353393e+50T)
Unknown0.0% ($18.9M)

Filing History

QuarterFiling DatePortfolio ValueHoldings
Q4 2025Feb 13, 2026$309.3M14

Fund Information

CIK0002003147
Most Recent FilingFeb 13, 2026
Number of Filings1

Davern Capital Partners, LP is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $309.3M across 14 holdings. The largest position is PFIZER INC (PFE), representing 16.4% of the portfolio. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.